Recent Amyloid-Targeting Drug Approvals

Lecanemab (Leqembi) and Donanemab (Kisunla) are two of the latest FDA-approved amyloid-beta targeting therapies, designed to clear plaques and slow cognitive decline in early Alzheimer's disease.

Sources

• eastonad.ucla.edu
• fda.gov
• Donanemab Approved for Treatment of Early Alzheimer's | alz.org
• Donanemab, Kisunla, FDA approved, Alzheimer's drug - UCLA Easton Center
• FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk
• alzint.org

Open the full topic